IgA Nephropathy — Trials, FDA Actions & Pivotal Research

20 active IgA Nephropathy trials currently recruiting in the US, sourced from ClinicalTrials.gov.

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 12, 2026.

Recruiting trials by city

Cities where IgA Nephropathy trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.

Birmingham, AL Chula Vista, CA Denver, CO Doral, FL Palo Alto, CA

Active IgA Nephropathy trials

Currently recruiting US trials matching IgA Nephropathy, sourced live from ClinicalTrials.gov. We’ll add per-event articles here as those trials post results or hit primary completion.

Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

for IgA Nephropathy

Sponsor: NovelMed Therapeutics

Sex: All·Age: 18 - 65

Code: NCT06454110·Phase 2·Not Yet Recruiting

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

for Berger Disease

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 2 - 18

Code: NCT07498335·Phase 3·Not Yet Recruiting

Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

for IgAN

Sponsor: Sitala Bio LTD

Sex: All·Age: 18+

Code: NCT07606352·Phase 2·Not Yet Recruiting

IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection

for IgA Nephropathy

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 99

Code: NCT07481084·Not Yet Recruiting

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

for IgA Nephropathy

6 locations incl. Chula Vista

Sponsor: Jade Biosciences, Inc.

Sex: All·Age: 18 - 60

Code: NCT07541287·Phase 2·Recruiting

Apply to this trial

FXS6837 for the Treatment of IgAN Patients

for IgAN

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Sex: All·Age: 18+

Code: NCT07502638·Phase 2·Not Yet Recruiting

Efficacy and Safety Study of HS-10542 for IgA Nephropathy

for IgAN

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Sex: All·Age: 18 - 74

Code: NCT07474636·Phase 2·Not Yet Recruiting

Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.

for IgA Glomerulonephritis

Sponsor: Chinese PLA General Hospital

Sex: All·Age: 18+

Code: NCT07585981·Recruiting

Apply to this trial

Study of CM313 in Subject With IgA Nephropathy

for IgA Nephropathy

Sponsor: Keymed Biosciences Co.Ltd

Sex: All·Age: 18 - 75

Code: NCT06830395·Phase 2·Not Yet Recruiting

Nefecon and Ambrisentan in IgA Nephropathy

for IgA Nephropathy

Sponsor: The First Hospital of Jilin University

Sex: All·Age: 18 - 70

Code: NCT07030894·Phase 4·Recruiting

Apply to this trial

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

for IgAN

11 locations incl. Doral

Sponsor: ADARx Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06989359·Phase 2·Recruiting

Apply to this trial

Study of BHV-1400 in IgA Nephropathy

for IgA Nephropathy

14 locations incl. Farmington

Sponsor: Biohaven Therapeutics Ltd.

Sex: All·Age: 18 - 65

Code: NCT07054684·Phase 1·Recruiting

Apply to this trial

Atacicept in Multiple Glomerular Diseases

for pMN

1 location in Brisbane

Sponsor: Vera Therapeutics, Inc.

Sex: All·Age: 10+

Code: NCT06983028·Phase 2·Recruiting

Apply to this trial

Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study

for IgA Nephropathy

Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Sex: All·Age: 18+

Code: NCT06350630·Phase 2·Recruiting

Apply to this trial

Study of Ravulizumab in Pediatric Participants With Primary IgAN

for IgAN

2 locations incl. Palo Alto

Sponsor: Alexion Pharmaceuticals, Inc.

Sex: All·Age: 2 - 18

Code: NCT07024563·Phase 3·Recruiting

Apply to this trial

Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis

for ANCA Associated Vasculitis

Sponsor: Assistance Publique - Hôpitaux de Paris

Sex: All·Age: 18 - 90

Code: NCT07010250·Not Yet Recruiting

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

for IgA Nephropathy

Sponsor: Christian Medical College, Vellore, India

Sex: All·Age: 18 - 65

Code: NCT06676384·Phase 4·Recruiting

Apply to this trial

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

for IgA Nephropathy

Sponsor: Sinocelltech Ltd.

Sex: All·Age: 18+

Code: NCT06774664·Phase 1, Phase 2·Not Yet Recruiting

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

for IgA Nephropathy

37 locations incl. Birmingham

Sponsor: Calliditas Therapeutics AB

Sex: All·Age: 18+

Code: NCT06712407·Phase 4·Recruiting

Apply to this trial

IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients

for IgA Nephropathy

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

Sex: All·Age: 18+

Code: NCT06690359·EARLY_Phase 1·Not Yet Recruiting